Stockscreener 앱 받기
1.66
1.19%
-0.02
시간 외 거래:
1.68
0.02
+1.20%
전일 마감가:
$1.68
열려 있는:
$1.72
하루 거래량:
923.26K
Relative Volume:
0.67
시가총액:
$114.05M
수익:
$182.30K
순이익/손실:
$-108.09M
주가수익비율:
-0.6422
EPS:
-2.5849
순현금흐름:
$-89.08M
1주 성능:
-4.60%
1개월 성능:
+3.11%
6개월 성능:
-30.25%
1년 성능:
-13.99%
1일 변동 폭
$1.65
$1.77
1주일 범위
$1.65
$1.78
52주 변동 폭
$1.30
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.66 | 115.42M | 182.30K | -108.09M | -89.08M | -2.5849 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Inovio cut 16% of workforce over the past year as FDA decision looms on drug application - The Business Journals
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) - GlobeNewswire
Inovio Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:INO) 2026-03-13 - Seeking Alpha
Inovio Stock Up On Earnings, Pipeline Progress - Benzinga
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Inovio: Q4 Earnings Snapshot - theheraldreview.com
Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlight - GuruFocus
Inovio Pharmaceuticals (INO) Advances BLA Review for INO-3107 - GuruFocus
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - lelezard.com
Inovio Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
INO: INO-3107 BLA under FDA review; cash runway extended into Q4 2026 amid focused pipeline progress - TradingView
Earnings call transcript: Inovio Pharmaceuticals’ Q4 2025 results highlight cost reductions - Investing.com
Inovio: Fourth Quarter Earnings Overview - Bitget
INO Advances INO-3107 Amid Financial Adjustments - GuruFocus
Inovio, Akeso partner on Phase 2 trial of new immunotherapy for glioblastoma - Rare Cancer News
INOVIO Pharmaceuticals reveals Q4 and full-year 2025 results amid operational shifts - Traders Union
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - PR Newswire
Inovio (NASDAQ: INO) details DNA medicine pipeline, INO-3107 FDA review and cash risk - Stock Titan
Bronstein, Gewirtz & Grossman LLC Urges Inovio - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain OfficersINO - ChartMill
INOVIO and Akeso Partner to Study New Glioblastoma Therapy - MyChesCo
INO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - The Malaysian Reserve
Inovio Pharmaceuticals (INO) Set to Announce Q4 Earnings - GuruFocus
Lawsuit Notice: Investors who lost money with shares of Inovio - openPR.com
Risk Off: Is Inovio Pharmaceuticals Inc a momentum stockBond Market & Weekly Momentum Picks - baoquankhu1.vn
INO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Ph - GuruFocus
DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - ACCESS Newswire
Inovio at The Citizens Life Sciences Conference: Strategic Insights on INO-3107 - Investing.com
INO: INO-3107 shows strong efficacy for RRP, with FDA review and commercial launch preparations underway - TradingView
Inovio Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your RightsINO - PR Newswire
2026-03-10 | INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:INO | Press Release - Stockhouse
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PomDoctor and Inovio and Encourages Investors to Contact the Firm - lincolnjournal.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PomDoctor and Inovio and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Levi & Korsinsky, LLP: Chronology of Events in the Inovio Pharmaceuticals Securities Class ... - Bluefield Daily Telegraph
Levi & Korsinsky, LLP: Chronology of Events in the Inovio Pharmaceuticals Securities Class Action - GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Inovio - GlobeNewswire
Inovio Pharmaceuticals, Inc. (GBM.F) Fundamental Analysis - Meyka
Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors - GlobeNewswire
INOVIO to share DNA medicine data on HPV surgical interventions and COVID - Stock Titan
2026-03-09 | INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:INO | Press Release - Stockhouse
INOVIO to Participate in Upcoming Scientific Conferences - The Malaysian Reserve
2026-03-08 | INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:INO | Press Release - Stockhouse
Inovio Pharmaceuticals (INO) Expected to Announce Earnings on Thursday - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Inovio - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ramaco Resources, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Inovio Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026 - Barchart.com
INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - BioSpace
Robbins LLP Urges INO Stockholders Who Lost Money Investing in Inovio Pharmaceuticals, Inc. to ... - Caledonian Record
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
1.21%
자본화:
|
볼륨(24시간):